Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved?

Research has shown there are plenty of perks of using a medication like Ozempic for weight loss. But, given that this is a drug, there are some potential downsides to consider, too. New research published in JAMA Network Open links GLP-1 receptor agonists—a class of medications that includes semaglutide medications like Ozempic and Wegovy—to a loss of bone density.